Vistagen Therapeutics Inc (NAS:VTGN)

Q2 2026 Vistagen Therapeutics Inc Earnings Call Transcript

Nov 13, 2025 / 10:00 PM GMT

Release Date Price: $3.8 (-6.63%)

Transcript 10-Q8-K

Key Points

Positve

Vistagen Therapeutics Inc (VTGN) has completed the randomized double-blind portion of its Palisade 3, phase 3 trial for fasodinol, targeting social anxiety disorder.
The company is on track to release top-line results from the Palisade 3 study by the end of the calendar year.
Vistagen has $77.2 million in cash equivalents and marketable securities, which is expected to cover all known aspects of the ongoing Palisade program.
The company is preparing for potential NDA submission if the Palisade program is successful.
Vistagen has welcomed Paul Edi to its board of directors, bringing valuable experience in FDA approvals and strategic transactions.

Negative

The company acknowledges that forward-looking statements involve risks and uncertainties, and actual results could differ materially.
There is no expectation that fasodinol will fall within the typical scope of the FDA's priority review voucher program.
Some clinical trial sites were terminated due to performance issues or as part of a wind-down approach.
The company has not provided specific percentages for the number of people entering the open label phase between Palisade 2 and Palisade 3.
Vistagen is still in the process of determining the commercialization strategy for fasodinol, whether independently or with a partner.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VTGN.OQ - VistaGen Therapeutics Inc
Q2 2026 Vistagen Therapeutics Inc Earnings Call
Nov 13, 2025 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day everyone.

Thank you for standing by. Welcome to the VistaGen Therapeutics fiscal year 2026. Second quarter, corporate update, conference call, and webcast.

Please note that today's call is being recorded.

At this time I'd like to turn the call over to your host Mark McPartland, senior Vice President, Investor relations at VistaGen. Mark.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Good afternoon everyone and welcome to our conference call and webcast.

Earlier this afternoon, we filed our quarterly

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.